

# Maria G Tektonidou

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8252688/publications.pdf>

Version: 2024-02-01

201  
papers

14,408  
citations

38660

50  
h-index

21474

114  
g-index

206  
all docs

206  
docs citations

206  
times ranked

11507  
citing authors

#	ARTICLE	IF	CITATIONS
1	2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2019, 71, 1400-1412.	2.9	1,098
2	Joint European League Against Rheumatism and European Renal Association "European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1771-1782.	0.5	868
3	2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1151-1159.	0.5	759
4	Comparison of Evidence of Treatment Effects in Randomized and Nonrandomized Studies. <i>JAMA - Journal of the American Medical Association</i> , 2001, 286, 821.	3.8	730
5	EULAR recommendations for the management of antiphospholipid syndrome in adults. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1296-1304.	0.5	664
6	Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1011-1018.	0.5	610
7	EULAR recommendations for women's health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 476-485.	0.5	590
8	Complement and tissue factor "enriched neutrophil extracellular traps are key drivers in COVID-19 immunothrombosis. <i>Journal of Clinical Investigation</i> , 2020, 130, 6151-6157.	3.9	580
9	EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 2074-2082.	0.5	578
10	Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: Report of a Task Force at the 13th International Congress on Antiphospholipid Antibodies. <i>Lupus</i> , 2011, 20, 206-218.	0.8	467
11	Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 2083-2089.	0.5	424
12	Risk of End-stage Renal Disease in Patients With Lupus Nephritis, 1971 "2015: A Systematic Review and Bayesian Meta-analysis. <i>Arthritis and Rheumatology</i> , 2016, 68, 1432-1441.	2.9	352
13	Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies. <i>Arthritis and Rheumatism</i> , 2009, 61, 29-36.	6.7	296
14	14th International Congress on Antiphospholipid Antibodies Task Force Report on Antiphospholipid Syndrome Treatment Trends. <i>Autoimmunity Reviews</i> , 2014, 13, 685-696.	2.5	290
15	Antiphospholipid syndrome nephropathy in patients with systemic lupus erythematosus and antiphospholipid antibodies: Prevalence, clinical associations, and long-term outcome. <i>Arthritis and Rheumatism</i> , 2004, 50, 2569-2579.	6.7	226
16	Libman-Sacks Endocarditis in Systemic Lupus Erythematosus: Prevalence, Associations, and Evolution. <i>American Journal of Medicine</i> , 2007, 120, 636-642.	0.6	196
17	The relevance of "non-criteria" clinical manifestations of antiphospholipid syndrome: 14th International Congress on Antiphospholipid Antibodies Technical Task Force Report on Antiphospholipid Syndrome Clinical Features. <i>Autoimmunity Reviews</i> , 2015, 14, 401-414.	2.5	194
18	Efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies: An international and collaborative meta-analysis. <i>Autoimmunity Reviews</i> , 2014, 13, 281-291.	2.5	166

#	ARTICLE	IF	CITATIONS
19	Long-term follow-up of the MAINTAIN Nephritis Trial, comparing azathioprine and mycophenolate mofetil as maintenance therapy of lupus nephritis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 526-531.	0.5	157
20	A proteinuria cut-off level of 0.7 g/day after 12 months of treatment best predicts long-term renal outcome in lupus nephritis: data from the MAINTAIN Nephritis Trial. <i>Lupus Science and Medicine</i> , 2015, 2, e000123-e000123.	1.1	155
21	Survival in adults and children with systemic lupus erythematosus: a systematic review and Bayesian meta-analysis of studies from 1950 to 2016. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 2009-2016.	0.5	155
22	Burden of Serious Infections in Adults With Systemic Lupus Erythematosus: A National Population-Based Study, 1996-2011. <i>Arthritis Care and Research</i> , 2015, 67, 1078-1085.	1.5	138
23	Asymptomatic avascular necrosis in patients with primary antiphospholipid syndrome in the absence of corticosteroid use: A prospective study by magnetic resonance imaging. <i>Arthritis and Rheumatism</i> , 2003, 48, 732-736.	6.7	128
24	EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 768-779.	0.5	128
25	Patient-level analysis of five international cohorts further confirms the efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies. <i>Autoimmunity Reviews</i> , 2015, 14, 192-200.	2.5	118
26	Cognitive Deficits in Patients With Antiphospholipid Syndrome. <i>Archives of Internal Medicine</i> , 2006, 166, 2278.	4.3	112
27	Combined genetic and transcriptome analysis of patients with SLE: distinct, targetable signatures for susceptibility and severity. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1079-1089.	0.5	109
28	Atherosclerosis in premenopausal women with antiphospholipid syndrome and systemic lupus erythematosus: a controlled study. <i>British Journal of Rheumatology</i> , 2003, 42, 645-651.	2.5	99
29	Presence of systemic autoimmune disorders in patients with autoimmune thyroid diseases. <i>Annals of the Rheumatic Diseases</i> , 2004, 63, 1159-1161.	0.5	97
30	Renal Involvement in the Antiphospholipid Syndrome (APS)-APS Nephropathy. <i>Clinical Reviews in Allergy and Immunology</i> , 2009, 36, 131-140.	2.9	96
31	Task Force on Catastrophic Antiphospholipid Syndrome (APS) and Non-criteria APS Manifestations (II): thrombocytopenia and skin manifestations. <i>Lupus</i> , 2011, 20, 174-181.	0.8	93
32	Task Force on Catastrophic Antiphospholipid Syndrome (APS) and Non-criteria APS Manifestations (I): catastrophic APS, APS nephropathy and heart valve lesions. <i>Lupus</i> , 2011, 20, 165-173.	0.8	91
33	Microvascular abnormalities in Sjögren's syndrome: nailfold capillaroscopy. <i>Rheumatology</i> , 1999, 38, 826-830.	0.9	87
34	Subclinical atherosclerosis in Systemic Lupus Erythematosus: Comparable risk with Diabetes Mellitus and Rheumatoid Arthritis. <i>Autoimmunity Reviews</i> , 2017, 16, 308-312.	2.5	83
35	Long-term outcomes in systemic lupus erythematosus: trends over time and major contributors. <i>Rheumatology</i> , 2020, 59, v29-v38.	0.9	80
36	16th International Congress on Antiphospholipid Antibodies Task Force Report on Antiphospholipid Syndrome Treatment Trends. <i>Lupus</i> , 2020, 29, 1571-1593.	0.8	80

#	ARTICLE	IF	CITATIONS
37	The adjusted global antiphospholipid syndrome score (aGAPSS) and the risk of recurrent thrombosis: Results from the APS ACTION cohort. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 49, 464-468.	1.6	79
38	The effect of hydroxychloroquine on thrombosis prevention and antiphospholipid antibody levels in primary antiphospholipid syndrome: A pilot open label randomized prospective study. <i>Autoimmunity Reviews</i> , 2020, 19, 102491.	2.5	75
39	Low-dose aspirin vs low-dose aspirin plus low-intensity warfarin in thromboprophylaxis: a prospective, multicentre, randomized, open, controlled trial in patients positive for antiphospholipid antibodies (ALIWAPAS). <i>Rheumatology</i> , 2014, 53, 275-284.	0.9	71
40	The effect of triple therapy on the mortality of catastrophic anti-phospholipid syndrome patients. <i>Rheumatology</i> , 2018, 57, 1264-1270.	0.9	70
41	Sleep Disturbances and Interleukin 6 Receptor Inhibition in Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2012, 39, 60-62.	1.0	66
42	Systemic lupus erythematosus: state of the art on clinical practice guidelines. <i>RMD Open</i> , 2019, 4, e000793.	1.8	66
43	Peripheral neuropathy in two patients with rheumatoid arthritis receiving infliximab treatment. <i>Clinical Rheumatology</i> , 2006, 26, 258-260.	1.0	64
44	Effect of anti-TNF treatment on body composition and serum adiponectin levels of women with rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2008, 27, 795-797.	1.0	64
45	Expanding the therapeutic options for renal involvement in lupus: eculizumab, available evidence. <i>Rheumatology International</i> , 2017, 37, 1249-1255.	1.5	61
46	Development of a New International Antiphospholipid Syndrome Classification Criteria Phase I/II Report: Generation and Reduction of Candidate Criteria. <i>Arthritis Care and Research</i> , 2021, 73, 1490-1501.	1.5	60
47	Low disease activity“irrespective of serologic status at baseline“associated with reduction of corticosteroid dose and number of flares in patients with systemic lupus erythematosus treated with belimumab: A real-life observational study. <i>Seminars in Arthritis and Rheumatism</i> , 2018, 48, 467-474.	1.6	59
48	Antiphospholipid syndrome (APS) nephropathy in catastrophic, primary, and systemic lupus erythematosus-related APS. <i>Journal of Rheumatology</i> , 2008, 35, 1983-8.	1.0	58
49	Leishmaniasis, Autoimmune Rheumatic Disease, and Anti“Tumor Necrosis Factor Therapy, Europe. <i>Emerging Infectious Diseases</i> , 2006, 15, 956-959.	2.0	57
50	Sleep disturbances in adults with arthritis: Prevalence, mediators, and subgroups at greatest risk. Data from the 2007 National Health Interview Survey. <i>Arthritis Care and Research</i> , 2011, 63, 247-260.	1.5	53
51	Right ventricular diastolic dysfunction in patients with anticardiolipin antibodies and antiphospholipid syndrome. <i>Annals of the Rheumatic Diseases</i> , 2001, 60, 43-48.	0.5	52
52	Antiphospholipid Syndrome Nephropathy: From Pathogenesis to Treatment. <i>Frontiers in Immunology</i> , 2018, 9, 1181.	2.2	52
53	Management of thrombotic and obstetric antiphospholipid syndrome: a systematic literature review informing the EULAR recommendations for the management of antiphospholipid syndrome in adults. <i>RMD Open</i> , 2019, 5, e000924.	1.8	52
54	Hydroxychloroquine in the primary thrombosis prophylaxis of antiphospholipid antibody positive patients without systemic autoimmune disease. <i>Lupus</i> , 2018, 27, 399-406.	0.8	51

#	ARTICLE	IF	CITATIONS
55	B-cell activating factor and related genetic variants in lupus related atherosclerosis. <i>Journal of Autoimmunity</i> , 2018, 92, 87-92.	3.0	51
56	Increased adenosine-to-inosine RNA editing in rheumatoid arthritis. <i>Journal of Autoimmunity</i> , 2020, 106, 102329.	3.0	51
57	Cardiovascular magnetic resonance imaging pattern at the time of diagnosis of treatment naïve patients with connective tissue diseases. <i>International Journal of Cardiology</i> , 2017, 236, 151-156.	0.8	45
58	Suicidal ideation among adults with arthritis: Prevalence and subgroups at highest risk. Data from the 2007-2008 National Health and Nutrition Examination Survey. <i>Arthritis Care and Research</i> , 2011, 63, 1322-1333.	1.5	44
59	Visceral leishmaniasis in a patient with psoriatic arthritis treated with infliximab: reactivation of a latent infection?. <i>Clinical Rheumatology</i> , 2008, 27, 541-542.	1.0	43
60	Repeat kidney biopsies fail to detect differences between azathioprine and mycophenolate mofetil maintenance therapy for lupus nephritis: data from the MAINTAIN Nephritis Trial. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 1924-1930.	0.4	43
61	Brief Report: Trends in Hospitalizations Due to Acute Coronary Syndromes and Stroke in Patients With Systemic Lupus Erythematosus, 1996 to 2012. <i>Arthritis and Rheumatology</i> , 2016, 68, 2680-2685.	2.9	43
62	Type I Interferon Signature in Primary Antiphospholipid Syndrome: Clinical and Laboratory Associations. <i>Frontiers in Immunology</i> , 2019, 10, 487.	2.2	43
63	Better outcomes of COVID-19 in vaccinated compared to unvaccinated patients with systemic rheumatic diseases. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1013-1016.	0.5	43
64	Treatment adherence of patients with systemic rheumatic diseases in COVID-19 pandemic. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, e60-e60.	0.5	41
65	Cardiovascular magnetic resonance detects silent heart disease missed by echocardiography in systemic lupus erythematosus. <i>Lupus</i> , 2018, 27, 564-571.	0.8	39
66	Characteristics of Patients With Antiphospholipid Antibody Positivity in the APS ACTION International Clinical Database and Repository. <i>Arthritis Care and Research</i> , 2022, 74, 324-335.	1.5	39
67	Antiphospholipid syndrome: state of the art on clinical practice guidelines. <i>RMD Open</i> , 2018, 4, e000785.	1.8	38
68	Emerging Therapies in Antiphospholipid Syndrome. <i>Current Rheumatology Reports</i> , 2016, 18, 22.	2.1	37
69	The Impact of Systemic Lupus Erythematosus on the Clinical Phenotype of Antiphospholipid Antibody-Positive Patients: Results From the AntiPhospholipid Syndrome Alliance for Clinical Trials and International Clinical Database and Repository. <i>Arthritis Care and Research</i> , 2019, 71, 134-141.	1.5	37
70	European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) SLE classification criteria item performance. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 775-781.	0.5	37
71	Cardiovascular disease risk in antiphospholipid syndrome: Thrombo-inflammation and atherothrombosis. <i>Journal of Autoimmunity</i> , 2022, 128, 102813.	3.0	37
72	Antibodies to beta 2-glycoprotein-I: urea resistance, binding specificity, and association with thrombosis. <i>Journal of Clinical Immunology</i> , 1998, 18, 380-391.	2.0	36

#	ARTICLE	IF	CITATIONS
73	Evolution of cardiac dysfunction in patients with antiphospholipid antibodies and/or antiphospholipid syndrome: A 10-year follow-up study. <i>Seminars in Arthritis and Rheumatism</i> , 2014, 43, 558-565.	1.6	36
74	Myositis autoantibody profiles and their clinical associations in Greek patients with inflammatory myopathies. <i>Clinical Rheumatology</i> , 2019, 38, 125-132.	1.0	35
75	Performance of the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in early disease, across sexes and ethnicities. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1333-1339.	0.5	35
76	Validation of new biomarkers in systemic autoimmune diseases. <i>Nature Reviews Rheumatology</i> , 2011, 7, 708-717.	3.5	34
77	Predictors of morbidity and mortality in early systemic sclerosis: Long-term follow-up data from a single-centre inception cohort. <i>Autoimmunity Reviews</i> , 2018, 17, 816-820.	2.5	34
78	Increased levels of soluble TNF-like cytokine 1A in ankylosing spondylitis. <i>Rheumatology</i> , 2013, 52, 448-451.	0.9	33
79	All-cause mortality in systemic rheumatic diseases under treatment compared with the general population, 2015-2019. <i>RMD Open</i> , 2021, 7, e001694.	1.8	33
80	Immunologic factors in the pathogenesis of osteonecrosis. <i>Orthopedic Clinics of North America</i> , 2004, 35, 259-263.	0.5	30
81	Carotid and femoral atherosclerosis in antiphospholipid syndrome: Equivalent risk with diabetes mellitus in a case-control study. <i>Seminars in Arthritis and Rheumatism</i> , 2018, 47, 883-889.	1.6	30
82	Factors associated with first thrombosis in patients presenting with obstetric antiphospholipid syndrome (APS) in the APS Alliance for Clinical Trials and International Networking Clinical Database and Repository: a retrospective study. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2019, 126, 656-661.	1.1	29
83	Effective DNA damage response after acute but not chronic immune challenge: SARS-CoV-2 vaccine versus Systemic Lupus Erythematosus. <i>Clinical Immunology</i> , 2021, 229, 108765.	1.4	29
84	Cluster analysis for the identification of clinical phenotypes among antiphospholipid antibody-positive patients from the APS ACTION Registry. <i>Lupus</i> , 2020, 29, 1353-1363.	0.8	28
85	The impact of upper limb exercise on function, daily activities and quality of life in systemic lupus erythematosus: a pilot randomised controlled trial. <i>RMD Open</i> , 2020, 6, e001141.	1.8	28
86	COVID-19 vaccine safety and nocebo-prone associated hesitancy in patients with systemic rheumatic diseases: a cross-sectional study. <i>Rheumatology International</i> , 2022, 42, 31-39.	1.5	28
87	Identification and treatment of APS renal involvement. <i>Lupus</i> , 2014, 23, 1276-1278.	0.8	27
88	Type I interferon gene expression in antiphospholipid syndrome: Pathogenetic, clinical and therapeutic implications. <i>Journal of Autoimmunity</i> , 2019, 104, 102311.	3.0	26
89	Higher depression rates and similar cardiovascular comorbidity in psoriatic arthritis compared with rheumatoid arthritis and diabetes mellitus. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2020, 12, 1759720X2097697.	1.2	26
90	Brief Report: Drug-Free Long-Term Remission in Severe Behçet's Disease Following Withdrawal of Successful Anti-Tumor Necrosis Factor Treatment. <i>Arthritis and Rheumatology</i> , 2017, 69, 2380-2385.	2.9	25

#	ARTICLE	IF	CITATIONS
91	Cardiac involvement in antiphospholipid syndrome: The diagnostic role of noninvasive cardiac imaging. <i>Seminars in Arthritis and Rheumatism</i> , 2016, 45, 611-616.	1.6	24
92	Prevalence of comorbidities in systemic sclerosis versus rheumatoid arthritis: a comparative, multicenter, matched-cohort study. <i>Arthritis Research and Therapy</i> , 2018, 20, 267.	1.6	24
93	Comparable or higher prevalence of comorbidities in antiphospholipid syndrome <i>vs</i> rheumatoid arthritis: a multicenter, case-control study. <i>Rheumatology</i> , 2021, 60, 170-178.	0.9	24
94	Progression of subclinical atherosclerosis in systemic lupus erythematosus versus rheumatoid arthritis: the impact of low disease activity. <i>Rheumatology</i> , 2018, 57, 2158-2166.	0.9	23
95	Management of Non-criteria Manifestations in Antiphospholipid Syndrome. <i>Current Rheumatology Reports</i> , 2020, 22, 51.	2.1	22
96	Does seronegative obstetric APS exist? <i>and</i> <i>cons</i> . <i>Autoimmunity Reviews</i> , 2019, 18, 102407.	2.5	21
97	Effect of belimumab treatment on antiphospholipid antibody levels: post-hoc analysis based on two randomised placebo-controlled trials in systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 304-307.	0.5	21
98	COVID-19 and antiphospholipid antibodies: A position statement and management guidance from AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION). <i>Lupus</i> , 2021, 30, 2276-2285.	0.8	21
99	Underperformance of clinical risk scores in identifying vascular ultrasound-based high cardiovascular risk in systemic lupus erythematosus. <i>European Journal of Preventive Cardiology</i> , 2020, , 204748732090665.	0.8	20
100	Alterations in cortisol and interleukin-6 secretion in patients with COVID-19 suggestive of neuroendocrine-immune adaptations. <i>Endocrine</i> , 2022, 75, 317-327.	1.1	20
101	An Update on Antiphospholipid Syndrome. <i>Current Rheumatology Reports</i> , 2021, 23, 84.	2.1	20
102	Antiphospholipid Antibody Profile Stability Over Time: Prospective Results From the APS ACTION Clinical Database and Repository. <i>Journal of Rheumatology</i> , 2021, 48, 541-547.	1.0	19
103	15th International Congress on Antiphospholipid Antibodies Task Force on Antiphospholipid Syndrome Treatment Trends Report. , 2017, , 317-338.		19
104	Clinical importance of antibodies against platelet activating factor in antiphospholipid syndrome manifestations. <i>European Journal of Clinical Investigation</i> , 2000, 30, 646-652.	1.7	18
105	Profiles of criteria and non-criteria anti-phospholipid autoantibodies are associated with clinical phenotypes of the antiphospholipid syndrome. <i>Autoimmunity Highlights</i> , 2020, 11, 8.	3.9	18
106	Clinical outcomes of breakthrough COVID-19 after booster vaccination in patients with systemic rheumatic diseases. <i>RMD Open</i> , 2022, 8, e002279.	1.8	18
107	Reiter's syndrome during intravesical BCG therapy for bladder carcinoma. <i>Clinical Rheumatology</i> , 2007, 26, 1368-1369.	1.0	17
108	Underperformance of clinical risk scores in identifying vascular ultrasound-based high cardiovascular risk in systemic lupus erythematosus. <i>European Journal of Preventive Cardiology</i> , 2021, 28, 346-352.	0.8	17

#	ARTICLE	IF	CITATIONS
109	Physician Global Assessment International Standardisation COnsensus in Systemic Lupus Erythematosus: the PISCOS study. <i>Lancet Rheumatology</i> , The, 2022, 4, e441-e449.	2.2	17
110	Validity of clinical associations of biomarkers in translational research studies: the case of systemic autoimmune diseases. <i>Arthritis Research and Therapy</i> , 2010, 12, R179.	1.6	15
111	Silent Myocardial Perfusion Abnormalities Detected by Stress Cardiovascular Magnetic Resonance in Antiphospholipid Syndrome: A Case-Control Study. <i>Journal of Clinical Medicine</i> , 2019, 8, 1084.	1.0	15
112	Joint microwave radiometry for inflammatory arthritis assessment. <i>Rheumatology</i> , 2020, 59, 839-844.	0.9	15
113	Increased influenza vaccination rates in patients with autoimmune rheumatic diseases during the Covid-19 pandemic: a cross-sectional study. <i>Rheumatology International</i> , 2021, 41, 895-902.	1.5	15
114	HLA associations of anti-beta2 glycoprotein I response in a Greek cohort with antiphospholipid syndrome and meta-analysis of four ethnic groups. <i>Human Immunology</i> , 1999, 60, 1274-1280.	1.2	14
115	Adenosine-to-inosine RNA editing contributes to type I interferon responses in systemic sclerosis. <i>Journal of Autoimmunity</i> , 2021, 125, 102755.	3.0	14
116	Biologic treatment for rheumatic disease: real-world big data analysis from the Greek country-wide prescription database. <i>Clinical and Experimental Rheumatology</i> , 2017, 35, 579-585.	0.4	14
117	Independent association of low IFN $\gamma$ 1 gene expression and type I IFN score/IFN $\gamma$ 1 ratio with obstetric manifestations and triple antiphospholipid antibody positivity in primary antiphospholipid syndrome. <i>Clinical Immunology</i> , 2019, 209, 108265.	1.4	13
118	The comparison of real world and core laboratory antiphospholipid antibody ELISA results from antiphospholipid syndrome alliance for clinical trials & international networking (APS ACTION) clinical database and repository analysis. <i>Thrombosis Research</i> , 2019, 175, 32-36.	0.8	13
119	Belimumab as Add-on Therapy in Lupus Nephritis. <i>New England Journal of Medicine</i> , 2020, 383, 1184-1185.	13.9	13
120	Multicenter Cross-sectional Study of Patients with Rheumatoid Arthritis in Greece: Results from a cohort of 2.491 patients. <i>Mediterranean Journal of Rheumatology</i> , 2018, 29, 27-37.	0.3	13
121	Cardiovascular risk management in antiphospholipid syndrome: trends over time and comparison with rheumatoid arthritis and diabetes mellitus. <i>Lupus Science and Medicine</i> , 2021, 8, e000579.	1.1	13
122	Real-time three-dimensional echocardiography in evaluating Libman-Sacks vegetations. <i>European Journal of Echocardiography</i> , 2010, 11, 184-185.	2.3	12
123	Interhospital variation in mortality among patients with systemic lupus erythematosus and sepsis in the USA. <i>Rheumatology</i> , 2019, 58, 1794-1801.	0.9	12
124	Growth differentiation factor 15 (GDF-15) as potential cardiovascular risk biomarker in antiphospholipid syndrome. <i>Rheumatology</i> , 2021, 61, 394-399.	0.9	12
125	Psoriasis as an adverse reaction to biologic agents beyond anti-TNF $\alpha$ therapy. <i>European Journal of Dermatology</i> , 2021, 31, 307-317.	0.3	12
126	Diabetes mellitus and cardiovascular risk management in patients with rheumatoid arthritis: an international audit. <i>RMD Open</i> , 2021, 7, e001724.	1.8	12



#	ARTICLE	IF	CITATIONS
127	Atherosclerosis progression in antiphospholipid syndrome is comparable to diabetes mellitus: a 3-åyear prospective study. <i>Rheumatology</i> , 2022, 61, 3408-3413.	0.9	12
128	Vasculitis beyond aortitis in IgG4-related disease (IgG4-RD): case report and review of the literature. <i>Clinical Rheumatology</i> , 2021, 40, 1167-1173.	1.0	11
129	Real-world evidence of the impact of adalimumab on work productivity and sleep measures in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2020, 12, 1759720X2094908.	1.2	10
130	Treatment patterns and achievement of the treat-to-target goals in a real-life rheumatoid arthritis patient cohort: data from 1317 patients. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2020, 12, 1759720X2093713.	1.2	10
131	Combined Brain-Heart Magnetic Resonance Imaging in Autoimmune Rheumatic Disease Patients with Cardiac Symptoms: Hypothesis Generating Insights from a Cross-Sectional Study. <i>Journal of Clinical Medicine</i> , 2020, 9, 447.	1.0	10
132	Appropriate Screening for Leishmaniasis before Immunosuppressive Treatments. <i>Emerging Infectious Diseases</i> , 2009, 15, 1706a-1706.	2.0	9
133	Asymptomatic Bacteriuria in Women With Autoimmune Rheumatic Disease: Prevalence, Risk Factors, and Clinical Significance. <i>Clinical Infectious Diseases</i> , 2015, 60, 868-874.	2.9	9
134	Comparison of real world and core laboratory lupus anticoagulant results from the Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) clinical database and repository. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 2069-2080.	1.9	9
135	Myocardial Involvement in Rheumatic Disorders. <i>Current Heart Failure Reports</i> , 2020, 17, 171-180.	1.3	9
136	Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION): 10-Year Update. <i>Current Rheumatology Reports</i> , 2021, 23, 45.	2.1	9
137	Adrenocortical dysfunction in rheumatoid arthritis: Å narrative review and future directions. <i>European Journal of Clinical Investigation</i> , 2022, 52, e13635.	1.7	9
138	Nocebo-Prone Behaviour in Patients with Autoimmune Rheumatic Diseases during the COVID-19 Pandemic. <i>Mediterranean Journal of Rheumatology</i> , 2020, 31, 288.	0.3	9
139	Oral antiviral treatment in patients with systemic rheumatic disease at risk for development of severe COVID-19: a case series. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1477-1479.	0.5	9
140	Pregnancy outcomes in antiphospholipid antibody positive patients: prospective results from the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (ÅRegistryÅ™). <i>Lupus Science and Medicine</i> , 2022, 9, e000633.	1.1	9
141	Introduction and switching of biologic agents are associated with antidepressant and anxiolytic medication use: data on 42 815 real-world patients with inflammatory rheumatic disease. <i>RMD Open</i> , 2020, 6, e001303.	1.8	8
142	Extensive fragmentation and re-organization of transcription in Systemic Lupus Erythematosus. <i>Scientific Reports</i> , 2020, 10, 16648.	1.6	8
143	B-cell oligoclonal expansions in renal tissue of patients with immune-mediated glomerular disease. <i>Clinical Immunology</i> , 2020, 217, 108488.	1.4	8
144	Incidence, risk factors and validation of the RABBIT score for serious infections in a cohort of 1557 patients with rheumatoid arthritis. <i>Rheumatology</i> , 2021, 60, 2223-2230.	0.9	8

#	ARTICLE	IF	CITATIONS
145	An international audit of the management of dyslipidaemia and hypertension in patients with rheumatoid arthritis: results from 19 countries. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 539-548.	1.4	8
146	Osteoarticular Manifestations of Antiphospholipid Syndrome. <i>Rheumatic Disease Clinics of North America</i> , 2006, 32, 523-535.	0.8	7
147	Depression and anxiety in a real-world psoriatic arthritis longitudinal study: should we focus more on patients' perception?. <i>Clinical and Experimental Rheumatology</i> , 0, , .	0.4	7
148	MALT lymphoma of the lacrimal gland in the context of systemic lupus erythematosus: complete remission after treatment with rituximab. <i>Lupus</i> , 2010, 19, 1243-1245.	0.8	6
149	Guillain-Barre syndrome presenting with sensory disturbance following a herpes virus infection: a case report. <i>Journal of Medical Case Reports</i> , 2011, 5, 563.	0.4	6
150	Anti-interleukin 6 Therapy Effect for Refractory Joint and Skin Involvement in Systemic Sclerosis: A Real-world, Single-center Experience. <i>Journal of Rheumatology</i> , 2022, 49, 68-73.	1.0	6
151	Prevention and Treatment of Thrombotic Antiphospholipid Syndrome. , 2017, , 223-233.		6
152	Presence of Other Autoimmune Diseases in Subjects with Autoimmune Thyroid Disease. <i>American Journal of Medicine</i> , 2010, 123, e23.	0.6	5
153	Retinal vascular calibers in contemporary patients with chronic systemic inflammatory diseases: The Greek REtinal Microcirculation (GREM) study. <i>Artery Research</i> , 2017, 18, 1.	0.3	5
154	Clinical value of amyloid-beta1-40 as a marker of thrombo-inflammation in antiphospholipid syndrome. <i>Rheumatology</i> , 2021, 60, 1669-1675.	0.9	5
155	Rare clinical manifestations in systemic lupus erythematosus: a review on frequency and clinical presentation. <i>Clinical and Experimental Rheumatology</i> , 2022, 40, 93-102.	0.4	5
156	Letter to the Editor. <i>Lupus</i> , 2003, 12, 723-724.	0.8	4
157	Combined brain/heart magnetic resonance imaging in antiphospholipid syndrome-two sides of the same coin. <i>Clinical Rheumatology</i> , 2021, 40, 2559-2568.	1.0	4
158	Impaired hand function and performance in activities of daily living in systemic lupus erythematosus, even in patients achieving lupus low disease activity state (LLDAS). <i>Rheumatology Advances in Practice</i> , 2021, 5, rkab029.	0.3	4
159	Treatment of Non-criteria Manifestations in Antiphospholipid Syndrome. , 2017, , 247-266.		4
160	Guideline: EULAR provided recommendations for thrombotic and obstetric antiphospholipid syndrome. <i>Annals of Internal Medicine</i> , 2019, 171, JC26.	2.0	3
161	JAK inhibitors: promising for a wider spectrum of autoimmune diseases?. <i>Lancet, The</i> , 2019, 394, 2047-2048.	6.3	3
162	Response to: â€œCorrespondence on â€œEULAR recommendations for the management of antiphospholipid syndrome in adultsâ€™ by Zhou <i>et al</i>. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, e249-e249.	0.5	3

#	ARTICLE	IF	CITATIONS
163	SLICC-Frailty Index is independently associated with impaired physical function, activities of daily living and quality of life measures. <i>Rheumatology</i> , 2022, 61, 3808-3813.	0.9	3
164	Axial psoriatic arthritis and ankylosing spondylitis: same or different? A real-world study with emphasis on comorbidities. <i>Clinical and Experimental Rheumatology</i> , 0, , .	0.4	3
165	Antiphospholipid syndrome-associated nephropathy in systemic lupus erythematosus. <i>International Journal of Clinical Rheumatology</i> , 2012, 7, 131-134.	0.3	2
166	Reply. <i>Arthritis and Rheumatology</i> , 2017, 69, 1705-1705.	2.9	2
167	Response to: "Association of subcutaneous belimumab and long-term antimalarial treatment reduces antiphospholipid antibodies levels in systemic lupus erythematosus: post-hoc analysis of a randomised placebo-controlled trial" comment on: "Effect of belimumab treatment on antiphospholipid antibody levels: post-hoc analysis based on two randomised placebo-controlled trials in systemic lupus erythematosus" by Chatzidionysiou et al. by Bettiol et al. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, e141-e141.	0.5	2
168	Stress perfusion Cardiac Magnetic Resonance in Patients with Antiphospholipid Syndrome. <i>Mediterranean Journal of Rheumatology</i> , 2018, 29, 99-102.	0.3	2
169	Outcomes of conventionally-treated systemic sclerosis patients eligible for autologous haematopoietic stem cell transplantation. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 29-33.	0.4	2
170	<i>Infections and Autoimmune Renal Diseases</i> . , 2015, , 929-942.		1
171	European League Against Rheumatism (EULAR) recommendations and EULAR/American College of Rheumatology criteria" documenting progress in lupus. <i>Rheumatology</i> , 2020, 60, 2976-2978.	0.9	1
172	Current understanding and future perspectives of brain"heart"kidney axis in psoriatic arthritis. <i>Rheumatology International</i> , 2020, 40, 1361-1368.	1.5	1
173	Response to: "Correspondence on "EULAR recommendations for the management of antiphospholipid syndrome in adults" by Gao and Qin. <i>Annals of the Rheumatic Diseases</i> , 2023, 82, e107-e107.	0.5	1
174	Appropriate Screening for Leishmaniasis before Immunosuppressive Treatments. <i>Emerging Infectious Diseases</i> , 2009, 15, 1706b-1707.	2.0	1
175	Task Force Report on the Management of Thrombosis in Antiphospholipid Syndrome. , 2012, , 167-179.		1
176	Task Force Report on Non-criteria Manifestations: Nephropathy. , 2012, , 207-221.		1
177	The effects of golimumab on work productivity and quality of life among work-active axial spondyloarthritis and psoriatic arthritis patients treated in the routine care in Greece: the "GO-UP" study. <i>Quality of Life Research</i> , 2022, 31, 1385-1399.	1.5	1
178	Impaired adrenal cortex reserve in patients with rheumatic and musculoskeletal diseases who relapse upon tapering of low glucocorticoid dose. <i>Clinical and Experimental Rheumatology</i> , 0, , .	0.4	1
179	Antiphospholipid syndrome nephropathy in antiphospholipid antibody-positive patients with systemic lupus erythematosus: Comment on the article by Tektonidou et al. <i>Arthritis and Rheumatism</i> , 2005, 52, 988-989.	6.7	0
180	A case with epilepsy, cognitive impairment, renal microangiopathy and high titres of anticentromere and anticardiolipin antibodies. <i>Lupus</i> , 2005, 14, 625-628.	0.8	0

#	ARTICLE	IF	CITATIONS
181	Osteoarticular Manifestations of Antiphospholipid Syndrome. , 2006, , 127-139.		0
182	Measures of Psychological Distress in Patients With Arthritis: Comment on the Article by Fullerâ€Thomson and Shaked. Arthritis Care and Research, 2010, 62, 140-141.	1.5	0
183	Methodological quality of studies of end-stage renal disease risks in lupus nephritis. Arthritis Research and Therapy, 2014, 16, A47.	1.6	0
184	Methodological Quality of Studies of Endstage Renal Disease in Lupus Nephritis, 1970 to 2015. Journal of Rheumatology, 2017, 44, 626-630.	1.0	0
185	CS-27â€...Mortality among patients with systemic lupus erythematosus hospitalized with sepsis varies widely among U.S. hospitals. , 2018, , .		0
186	OP0248â€...THE IMPACT OF EXERCISE ON HAND FUNCTION AND QUALITY OF LIFE OF PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: A RANDOMIZED CONTROLLED TRIAL. , 2019, , .		0
187	OP0297â€...ABERRANT ADENOSINE TO INOSINE RNA EDITING IN ACTIVE RHEUMATOID ARTHRITIS. , 2019, , .		0
188	AB0678â€...ANTIPROLIFERATIVE AND VASOACTIVE TREATMENT MODALITIES IN 457 CONSECUTIVE PATIENTS WITH SYSTEMIC SCLEROSIS FROM ACADEMIC CENTERS IN GREECE. , 2019, , .		0
189	OP0015â€...INCIDENCE, RISK FACTORS AND VALIDATION OF THE RABBIT SCORE FOR SERIOUS INFECTIONS IN A REAL LIFE PROSPECTIVE STUDY OF PATIENTSWITH RHEUMATOID ARTHRITIS: DATA FROM 1.549 PATIENTS. , 2019, , .		0
190	SAT0247â€...FEMALE SEX AND AGE AT DIAGNOSIS ARE ASSOCIATED WITH A DECREASED POSSIBILITY OF DRUG DISCONTINUATION IN GIANT CELL ARTERITIS: DATA FROM A MULTICENTER PROSPECTIVE COHORT OF 177 PATIENTS. , 2019, , .		0
191	SP0191â€...MANAGEMENT OF ADULT APS: RECOMMENDATIONS FROM AN EULAR TASK FORCE. , 2019, , .		0
192	O8â€...Performance of the EULAR/ACR 2019 classification criteria for systemic lupus erythematosus in men, ethnicities, and early disease. , 2020, , .		0
193	AB0421â€...Low rates of retention of biologic dmard monotherapy in patients with rheumatoid arthritisin real life settings. , 2018, , .		0
194	THU0102â€...High rates of residual disease activity despite current therapies in a real life rheumatoid arthritiscohort: data from 1096 patients. , 2018, , .		0
195	THU0427â€...Comparable cardiovascular disease and neoplasm rates but higher frequency of depression in systemic sclerosis versus rheumatoid arthritis: a multicentre comparative study of comorbidities. , 2018, , .		0
196	The Second Greek-Israeli Symposium on Autoimmunity and Rheumatology: Success Through Synergy. Israel Medical Association Journal, 2019, 21, 292-297.	0.1	0
197	Mechanics of early ventricular impairment in systemic sclerosis and the effects of peripheral arterial haemodynamics. Clinical and Experimental Rheumatology, 2019, 37 Suppl 119, 57-62.	0.4	0
198	Differential performance of nailfold video capillaroscopic parameters in the diagnosis and prognosis of systemic sclerosis. Clinical and Experimental Rheumatology, 2020, 38 Suppl 125, 29-39.	0.4	0

#	ARTICLE	IF	CITATIONS
199	Outcomes of conventionally-treated systemic sclerosis patients eligible for autologous haematopoietic stem cell transplantation. <i>Clinical and Experimental Rheumatology</i> , 2021, 39 Suppl 131, 29-33.	0.4	0
200	Axial psoriatic arthritis and ankylosing spondylitis: same or different? A real-world study with emphasis on comorbidities. <i>Clinical and Experimental Rheumatology</i> , 2021, , .	0.4	0
201	New Insights Into an Overlooked Entity: Long-Term Outcomes of Membranous Lupus Nephritis From a Single Institution Inception Cohort. <i>Frontiers in Medicine</i> , 2022, 9, 809533.	1.2	0